Pembrolizumab: all 1,753 studies that test it
Page 13 of 18. Open to participants first (418), then studies with results posted, then the rest; newest registration first within each.
- Dose Confirmation and Dose Expansion Phase 1 Study of IO-108 and IO-108 + Anti-PD-1 in Solid TumorsCompletedNCT05508100Phase 1
- Evaluating Pembrolizumab, Trastuzumab and FLOT as Perioperative Treatment of HER2-positive, Localized Esophagogastric AdenocarcinomaCompletedNCT05504720Phase 2
- Study of KBA1412 in Participants With Advanced Solid Malignant TumorsCompletedNCT05501821Phase 1
- Pembrolizumab, Belantamab and Dexamethasone in Refractory Multiple Myeloma.WithdrawnNCT05493618Phase 1/2
- Immunotherapy Combined With Radiotherapy for Metastatic SarcomaActive, not recruitingNCT05488366Early Phase 1
- Neoadjuvant Therapy of Pembrolizumab Plus Lenvatinib in Advanced RCCCompletedNCT05485896Phase 2
- Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant GliomaActive, not recruitingNCT05484622Phase 1
- Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid TumorsCompletedNCT05479812Phase 1
- Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian CancerActive, not recruitingNCT05467670Phase 2
- Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent GlioblastomaActive, not recruitingNCT05465954Phase 2
- ONC-392 and Pembrolizumab in Platinum Resistant Ovarian CancerActive, not recruitingNCT05446298Phase 2
- Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid TumorsActive, not recruitingNCT05438420Phase 1/2
- Antitumor Activity of Vactosertib in Combination With Pembrolizumab in Acral and Mucosal Melanoma Patients Progressed From Prior Immune Check Point InhibitorTerminatedNCT05436990Phase 2
- Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid TumorsWithdrawnNCT05431582Phase 1
- Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair SystemWithdrawnNCT05419817Phase 2
- Pembrolizumab in Muscle-invasive Bladder CancerActive, not recruitingNCT05406713Phase 2
- Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and AboveActive, not recruitingNCT05404945Phase 2
- A Study of NI-1801 in Patients with Mesothelin Expressing Solid CancersStatus unknownNCT05403554Phase 1
- Pembrolizumab and Lenvatinib for Resectable Hepatocellular CarcinomaActive, not recruitingNCT05389527Phase 2
- Pembrolizumab and Photodynamic Therapy in Previously Treated Metastatic Esophageal Squamous Cell CarcinomaStatus unknownNCT05386056Phase 2
- Study of Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-stage Small Cell Lung CancerActive, not recruitingNCT05384015Phase 2
- Neoadjuvant/Adjuvant Pembrolizumab Plus ChemotherapyActive, not recruitingNCT05383716Phase 2
- A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001)TerminatedNCT05382325Phase 1
- A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With PembrolizumabActive, not recruitingNCT05378425Phase 1
- Trial of LAVA-1207 in Patients With Therapy Refractory Metastatic Castration Resistant Prostate Cancer (mCRPC) Resistant Prostate CancerTerminatedNCT05369000Phase 1
- Pembrolizumab in Small Cell Carcinoma of Ovary - Hypercalcemic Type PatientCompletedNCT05368207Not applicable
- Pembrolizumab Plus Olaparib in LA-HNSCCActive, not recruitingNCT05366166Phase 2
- Seleno-L Methionine (SLM)-Axitinib-PembrolizumabActive, not recruitingNCT05363631Phase 1/2
- IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint InhibitorActive, not recruitingNCT05359445Phase 1
- Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung CancerActive, not recruitingNCT05353439Phase 1
- Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic MelanomaActive, not recruitingNCT05352672Phase 3
- Personalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)Active, not recruitingNCT05349890Phase 1
- A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid TumorsTerminatedNCT05346484Phase 1
- A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)CompletedNCT05342636Phase 1/2
- Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain MetastasesTerminatedNCT05341349Phase 1
- A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung CancerActive, not recruitingNCT05318573Phase 2
- Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid TumorsActive, not recruitingNCT05311618Phase 1
- A Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults With Unresectable or Metastatic MelanomaActive, not recruitingNCT05309421Phase 2
- Overcoming Primary Resistance to Immunotherapy in Metastatic MelanomaCompletedNCT05304546Phase 2
- Neoadjuvant Pembrolizumab Plus Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell CarcinomaCompletedNCT05302011Phase 2
- Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)CompletedNCT05298423Phase 3
- Pembrolizumab and Lenvatinib in Clear Cell Ovarian CancerActive, not recruitingNCT05296512Phase 2
- Phase II Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Cancer With LetrozoleActive, not recruitingNCT05286437Phase 2
- Trial of the Combination of GX-188E Vaccination, GX-I7 and Pembrolizumab in Patients With Advanced, Resectable HPV Type 16 and/or 18 Positive Head and Neck CancerActive, not recruitingNCT05286060Phase 2
- Efficacy and Safety of Pembrolizumab in Combination With Lenvatinib in Metastatic Uveal MElanoma Patients (PLUME)CompletedNCT05282901Phase 2
- A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal AdenocarcinomaCompletedNCT05273554Phase 1
- Chemotherapy and Pembrolizumab, Followed by Pembrolizumab and Olaparib As Firstline Therapy in Her-2 Negative Gastric/GEJ AdenocarcinomaCompletedNCT05268510Phase 2
- ASP-1929 Photoimmunotherapy Combined With Pembrolizumab in Patients With Recurrent Head and Neck Cancer, With or Without MetastasesTerminatedNCT05265013Phase 2
- Optimizing Pembrolizumab Therapy With Timing and Intensification With AxitinibWithdrawnNCT05263609Phase 2
- Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR MutationsCompletedNCT05258279Phase 2
- Combination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM)WithdrawnNCT05255666Phase 2
- Docetaxel/Pembrolizumab in Head and Neck Squamous Cell CarcinomaActive, not recruitingNCT05252429Phase 2
- Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)Active, not recruitingNCT05239741Phase 3
- Enfortumab Vedotin and Pembrolizumab in People With Bladder CancerActive, not recruitingNCT05239624Phase 2
- Radiotherapy in Combo With Chemo and Immunotherapy in Patients With PD-L1 Positive Metastatic TNBCWithdrawnNCT05233696Phase 2
- Pharmacokinetically-guided on the Individualization of Pembrolizumab Administration in the Treatment of Lung CancerCompletedNCT05226728Phase 1
- Pembrolizumab in Combination With R-ICE Chemotherapy in Relapsed/Refractory Diffuse Large B-cell LymphomaActive, not recruitingNCT05221645Phase 2
- RM-1995 Photoimmunotherapy, as Monotherapy or Combined With Pembrolizumab, in Patients With Advanced CuSCC and HNSCCWithdrawnNCT05220748Phase 1
- Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid TumorsActive, not recruitingNCT05215574Phase 1
- CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) AdenocarcinomaTerminatedNCT05207722Phase 1/2
- Pembrolizumab as Salvage Therapy for the Treatment of Multiple Myeloma in Patients Progressing on CAR-T Cell TherapyWithdrawnNCT05204160Phase 2
- Pembrolizumab and Olaparib in Homologous-recombination Deficient (HRD) Advanced Colorectal Cancer (CRC).Status unknownNCT05201612Phase 2
- T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid TumorsActive, not recruitingNCT05200559Phase 1/2
- NEOadjuvant PembRolizumab In Stratified Medicine - ColoRectal CancerActive, not recruitingNCT05197322Phase 2
- Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast CancerWithdrawnNCT05177796Phase 2
- A Study to Evaluate the Combination of YH003, YH001 and Pembrolizumab in Subjects with Advanced Solid TumorsCompletedNCT05176509Phase 1
- Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma PatientsActive, not recruitingNCT05176470Phase 1
- Nivolumab and Pembrolizumab Dose Optimisation in Solid Tumours With CURATE.AI Platform and Sequential ctDNA MeasurementsStatus unknownNCT05175235Phase 1/2
- JAB-BX102 Monotherapy and Combination With Pembrolizumab in Adult Patients With Advanced Solid TumorsCompletedNCT05174585Phase 1/2
- Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)Active, not recruitingNCT05173987Phase 3
- Dose Escalation Trial of Bexmarilimab (FP-1305) Plus Pembrolizumab in Non-Small Cell Lung CancerWithdrawnNCT05171062Phase 1
- Study of NG-350A Plus Pembrolizumab in Metastatic or Advanced Epithelial Tumours (FORTIFY)CompletedNCT05165433Phase 1
- Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With HR+/HER2- Metastatic Breast Cancer (mBCA)CompletedNCT05159778Phase 2
- Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian CancerStatus unknownNCT05158062Phase 2
- A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial CarcinosarcomaCompletedNCT05156268Phase 2
- A Study of Pembrolizumab With Lenvatinib in Women With Advanced Uterine CarcinosarcomaActive, not recruitingNCT05147558Phase 2
- Study to Evaluate Safety and Efficacy of TJ107 Combine With PD-1 in Patients With Solid TumorsActive, not recruitingNCT05145907Phase 2
- Pembrolizumab for Locally Advanced, Irresectable, Non-metastatic dMMR Colorectal CancersActive, not recruitingNCT05131919Phase 2
- A Study of NDI 1150-101 in Patients With Solid TumorsActive, not recruitingNCT05128487Phase 1/2
- A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid TumorsActive, not recruitingNCT05117476Phase 1
- Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung CancerTerminatedNCT05117242Phase 2
- Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer PatientsActive, not recruitingNCT05114421Phase 2
- Pembrolizumab and Lenvatinib in Patients With Advanced HCC Who Are Refractory to Atezolizumab and Bevacizumab/ IO-based TherapyCompletedNCT05101629Phase 2
- A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of Advanced Stage AdenocarcinomaSuspendedNCT05101356Phase 1/2
- Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)Active, not recruitingNCT05096663Phase 2/3
- SGT-53, Carboplatin, and Pembrolizumab for the Treatment of Metastatic Triple Negative Inflammatory Breast CancerWithdrawnNCT05093387Phase 1
- A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid TumorsTerminatedNCT05083481Phase 1
- A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid TumorsCompletedNCT05082610Phase 1
- ASTEROID: A Trial of ASTX660 in Combination With PembrolizumabActive, not recruitingNCT05082259Phase 1
- Brazilian Lung Immunotherapy StudyCompletedNCT05081674Phase 2
- A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor MalignanciesActive, not recruitingNCT05081609Phase 1/2
- A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC PatientsActive, not recruitingNCT05078931Phase 2
- A Study of Pembrolizumab and Cryoablation in People With MesotheliomaCompletedNCT05071014Phase 1
- Quaratusugene Ozeplasmid (Reqorsa) in Combination With Pembrolizumab in Previously Treated Non-Small Lung CancerTerminatedNCT05062980Phase 1
- A Study to Evaluate Safety and Efficacy of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma MultiformeActive, not recruitingNCT05053880Phase 1/2
- Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal AdenocarcinomaActive, not recruitingNCT05041153Early Phase 1
- Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDOActive, not recruitingNCT05033756Phase 2
- A Study of Belzutifan (MK-6482) as Monotherapy and in Combination With Lenvatinib (E7080/MK-7902) With or Without Pembrolizumab (MK-3475) in China Participants With Advanced Renal Cell Carcinoma (MK-6482-010)Active, not recruitingNCT05030506Phase 1
- A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18)CompletedNCT05017012Phase 1
- Gut Microbiota Reconstruction for NSCLC ImmunotherapyStatus unknownNCT05008861Phase 1